

Patient Report | FINAL



Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example** 

DOB 9/22/1972 Gender: Female

**Patient Identifiers:** 01234567890ABCD, 012345

**Visit Number (FIN):** 01234567890ABCD **Collection Date:** 01/01/2017 12:34

## **KRAS Mutation Detection**

ARUP test code 0040248

**KRAS Mutation Detection** 

Not Detected

A mutation in KRAS codons 12, 13, or 61 was not detected.

This result has been reviewed and approved by ■

ed and approved by

INTERPRETIVE INFORMATION: KRAS Mutation Detection

Oncogenic KRAS mutations have been linked with resistance to anti-EGFR therapies. Thus, determination of mutation status is useful in determining patient eligibility for this treatment.

Methodology: DNA is isolated from microdissected tumor tissue and amplified for segments of the KRAS gene covering codons 12, 13, and 61. Mutation status for these three codons is determined by pyrosequencing. Limitations: Mutations in other locations within the KRAS gene or in other genes will not be detected. Limit of detection: 10 percent mutant alleles.

Clinical Disclaimer: Results of this test must always be interpreted within the clinical context and other relevant data, and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

Block ID

SU20-2319 F2

H=High, L=Low, \*=Abnormal, C=Critical

4848



VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
KRAS Mutation Detection	20-120-110517	4/29/2020 1:58:00 PM	4/30/2020 2:56:34 PM	5/4/2020 10:17:00 AM
Block ID	20-120-110517	4/29/2020 1:58:00 PM	4/30/2020 2:56:34 PM	4/30/2020 3:50:00 PM

**END OF CHART** 

H=High, L=Low, \*=Abnormal, C=Critical